News

A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.

Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.

Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.

Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...

According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.

Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...

General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.

Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).

Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.

A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...